Next-Generation CAR T-Cell Therapies Shift Toward Multifunctional “Living Drugs” to Tackle Solid Tumors

Next-gen CAR T therapy moves toward multifunctional designs, using multitargeting and safety switches to improve outcomes in solid tumors and autoimmune diseases.

By: AXL Media

Published: Apr 30, 2026, 4:59 AM EDT

Source: Information for this report was sourced from News Medical Life Sciences and Molecular Therapy

The Evolution From Classical to Multifunctional Immune Engineering

Chimeric Antigen Receptor (CAR) T-cell therapy has entered a transformative era, moving away from the "classical" models first approved in 2017. While these early "living drugs" revolutionized the treatment of blood cancers, they often struggled with severe toxicities and limited effectiveness against solid tumors. A data-driven review published in Molecular Therapy analyzed 1,801 registered clinical trials to track this shift. The findings indicate that 533 of these trials now focus on multifunctional products designed to enhance both patient safety and therapeutic potency. These emergent modalities represent a strategic pivot toward engineering immune cells that can perform multiple tasks simultaneously, such as self-deactivating if they cause adverse reactions or secreting cytokines to survive longer within a hostile tumor environment.

Safety Mechanisms and the Rise of the Suicide Switch

One of the most critical advancements in multifunctional CAR T design is the integration of safety "on/off" or "suicide" switches, such as iCasp9. These technologies allow clinicians to externally trigger the deactivation of the engineered cells if a patient exhibits severe side effects, such as Cytokine Release Syndrome (CRS) or neurotoxicity. Although the review noted that these switches are rarely activated in actual clinical practice, their inclusion provides a vital safety net that was absent in first-generation treatments. By embedding these control mechanisms, researchers hope to mitigate the risks associated with high-potency treatments, particularly as they begin testing more aggressive designs meant to infiltrate dense, immunosuppressive solid tumors.

Multitargeting Strategies to Combat Tumor Escape

Efficacy enhancement through multitargeting has become the dominant trend in multifunctional research, accounting for 52% of such approaches in 2025. By engineering T cells to recognize two or more discrete tumor antigens simultaneously, scientists aim to prevent "antigen escape," a process where cancer cells hide by stopping the expression of a single target. While hematological targets like CD19 and BCMA remain prevalent, new clusters of research are focusing on Acute Myeloid Leukemia (AML) and various solid tumors. These complex designs often utilize "armored CARs" that endogenously secrete su...